TTI-109, a next-generation STAT3 inhibitor, demonstrated rapid conversion, dose-proportional PK, and improved GI tolerability in a phase I healthy volunteer study. Pharmacodynamic data showed reductions in key immune cell populations, supporting further development in dermatologic and GI diseases. IND filing for phase II is planned by year-end, with interim proof-of-concept data expected in 2028.
Based on Tvardi Therapeutics Study result Audio Transcript — Jul. 7 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.